Remove topic addiction
article thumbnail

What is Covered on the Addiction Medicine Blueprint?

Board Vitals - Pharmacist

The American Board of Preventive Medicine (ABPM) Addiction Medicine Certification Exam is a major step for physicians looking to practice in addiction medicine. What is the Addiction Medicine Blueprint? Developed by the ABPM, the blueprint outlines the core medical knowledge and skills expected of Addiction Medicine specialists.

article thumbnail

FDA Requires Updates to ADHD Medication Labeling

Pharma Leaders

The FDA said this action “is part of our ongoing efforts to minimize nonmedical use, addiction, overdose and the sharing of medications.” Related Topics

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Incannex engages QPS for CannQuit and ReneCann

Pharmaceutical Technology

The company will provide regulatory advice to Incannex, and manage clinical trials to develop CannQuit and ReneCann products to treat addiction and immune-disordered skin diseases. CannQuit-Opioid, named CheWell, combines CBD and an opioid antagonist/agonist in a water-soluble chewable tablet to treat opioid addiction.

article thumbnail

Beckley Psytech raises $80m for psychedelic meds development

pharmaphorum

The Oxford-based company had originally hoped to raise $50 million from the series B, and the scale of the financing is further evidence that repurposing psychedelic compounds as potential therapies for neuro-psychiatric disorders is a hot topic in biopharma. Beckley – formerly known as Beckley Canopy Therapeutics – raised £7.4

article thumbnail

Pain Management & Opioid CME Requirements by State

Board Vitals - Pharmacist

Each state’s medical licensing board has its own set of requirements for medical professionals to maintain their state medical licenses; some states require allotted CME hours on specific topics. This course must also include the subject of the risks of addiction associated with the use of Schedule II drugs. Kentucky – 4.5

article thumbnail

ACMT Toxicology Visual Pearl: Needle to Necrosis

ALiEM - Pharm Pearls

In patients with skin changes, consider topical wound care as well as further evaluation of deep tissue infections, osteomyelitis, and ischemia. Journal of Addiction Medicine 16(5):p 595-598, 9/10 2022. In patients with minimal response to naloxone, xylazine toxicity may be suspected [10]. Forensic Sci Int. 2014;240:1-8.

Hospitals 164
article thumbnail

Grünenthal takes non-opioid pain drug resiniferatoxin into phase 3

pharmaphorum

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of opioid drugs.